Takeda · Launch Intelligence
Portfolio cockpit
Six assets, six metrics, every figure sourced from public data.
Portfolio readiness
77/100
mean of 6 assets
Strongest asset
88
+2ptsFruzaqla
Watch list
58
+2ptsMezagitamab
Next milestone
Q4 2026
Oveporexton — FirstLight topline readout
Fruzaqla
LaunchedFruquintinib · Metastatic colorectal cancer (3L+)
88
+2 pts MoMNov 2023 (US), 2024 (EU/JP)
Regulatory 95
Trial momentum 70
Evidence 82
Access / HTA 84
Digital momentum 71
Competitive 74
Adzynma
LaunchedADAMTS13 recombinant · Congenital thrombotic thrombocytopenic purpura
86
+2 pts MoMNov 2023 (US), 2024 (EU)
Regulatory 94
Trial momentum 62
Evidence 68
Access / HTA 79
Digital momentum 52
Competitive 90
Eohilia
LaunchedBudesonide oral suspension · Eosinophilic esophagitis
83
+1 pts MoMFeb 2024 (US)
Regulatory 92
Trial momentum 64
Evidence 71
Access / HTA 72
Digital momentum 79
Competitive 81
Oveporexton
Pre-launchTAK-861 · Narcolepsy type 1
78
+4 pts MoMH2 2027 (expected)
Regulatory 84
Trial momentum 82
Evidence 76
Access / HTA 55
Digital momentum 81
Competitive 88
Rusfertide
Pre-launchRusfertide (Protagonist-partnered) · Polycythemia vera
71
+2 pts MoM2027-2028 (expected)
Regulatory 68
Trial momentum 79
Evidence 74
Access / HTA 48
Digital momentum 58
Competitive 72
Mezagitamab
Pre-launchTAK-079 · Immune thrombocytopenia / IgA nephropathy
58
+2 pts MoM2028 (expected)
Regulatory 55
Trial momentum 66
Evidence 61
Access / HTA 38
Digital momentum 49
Competitive 63
Metric matrix / 100
Every score computed from public-source facts. Hover an asset card for formulas.
| Asset | Regulatory | Trial momentum | Evidence | Access / HTA | Digital momentum | Competitive | Readiness |
|---|---|---|---|---|---|---|---|
| Fruzaqla Metastatic colorectal cancer (3L+) | 95 | 70 | 82 | 84 | 71 | 74 | 88 |
| Adzynma Congenital thrombotic thrombocytopenic purpura | 94 | 62 | 68 | 79 | 52 | 90 | 86 |
| Eohilia Eosinophilic esophagitis | 92 | 64 | 71 | 72 | 79 | 81 | 83 |
| Oveporexton Narcolepsy type 1 | 84 | 82 | 76 | 55 | 81 | 88 | 78 |
| Rusfertide Polycythemia vera | 68 | 79 | 74 | 48 | 58 | 72 | 71 |
| Mezagitamab Immune thrombocytopenia / IgA nephropathy | 55 | 66 | 61 | 38 | 49 | 63 | 58 |
Readiness ranking
Pre-launch Launched
Digital momentum ranking
Composite of search, KOL SoV, news velocity, community, payer chatter